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Arrhythmogenic Right Ventricular Cardiomyopathy 
(ARVC): ICDs Save Lives & Antitachycardia Pacing 
(ATP) is Highly Successful Regardless of Heart Rate 
Of 137 patients enrolled in a prospective North 
American ARVC registry, 108 received implantable 
cardioverter defibrillators (ICDs); 48 had 502 sustained 
episodes of ventricular arrhythmias (VAs) (489 
monomorphic and 13 polymorphic). In the ICD patients, 
independent predictors of VAs in follow-up included 
spontaneous sustained VAs before ICD implantation and 
T-wave inversions inferiorly. The only independent 
predictor for life-threatening VAs, defined as sustained 
ventricular tachycardia (VT) ≥240 beats/min or ventricular 
fibrillation, was a younger age at enrollment. Anti-
tachycardia pacing (ATP), independent of VT cycle 
length, was successful in terminating 92% of VT episodes. 
The authors concluded that in ARVC most VAs at follow-
up are monomorphic. Risk factors for VAs were 
spontaneous VAs before enrollment and a younger age at 
ICD implantation. ATP is highly successful in terminating 
VT, and all ICDs should be programmed for ATP, even for 
rapid VT (Link M et al, J Am Coll Cardiol 2014;64:119-125).  
 
PREVAIL: Left Atrial Appendage (LAA) Occlusion a 
Reasonable Alternative to Warfarin for Stroke 
Prevention in Non-Valvular Atrial Fibrillation? 
In the PROTECT AF trial in patients with nonvalvular 
atrial fibrillation (NVAF), LAA occlusion with the 
Watchman device was noninferior to warfarin for stroke 
prevention, but procedural safety was questionable. The 
PREVAIL study further assessed efficacy and safety of 
this device in patients with NVAF who had a CHADS2 
score ≥1-2. At 1½ years, the rate of first primary efficacy 
endpoint (composite of stroke, systemic embolism [SE], 
and cardiovascular/ unexplained death) was 0.064 in the 
device group (n=269) vs 0.063 in the control group 
(n=138) and did not achieve noninferiority criteria. The 
rate for the second primary efficacy endpoint (stroke or SE 
>7 days’ post-randomization) was 0.0253 vs 0.0200 (risk 
difference 0.0053), achieving noninferiority. Early safety 
events occurred in 2.2% of the device arm (lower than in 
PROTECT AF). All adverse effects were lower in 
PREVAIL trial than in PROTECT AF (4.2% vs 8.7%; p = 
0.004). Pericardial effusions requiring surgery decreased 
from 1.6% to 0.4% (p= 0.027), and those requiring peri-
cardiocentesis decreased from 2.9% to 1.5% (p=NS). The 
authors concluded that LAA occlusion was noninferior to 
warfarin for ischemic stroke prevention or SE >7 days’ 
post-procedure. Noninferiority was not achieved for 
overall efficacy but procedural safety improved (Holmes 
DR et al, J Am Coll Cardiol 2014;64:1-12). 
 
SCAAR: New-Generation Drug Eluting Stents (DES) 
in STEMI Patients Undergoing PCI is Safe in Short- 
and Long-Term Follow-up, with a Lower Risk of Early/ 
Late Stent Thrombosis and a Low Risk of Very Late 
Stent Thrombosis, Similar to Bare Metal Stents (BMS) 
In patients with acute ST-elevation myocardial 
infarction (STEMI), there is still some concern about the 
long-term safety of drug-eluting stents (DES). In the 
SCAAR registry, over 6 years (2007-2013), 34,147 
patients with STEMI were treated by primary 
percutaneous coronary intervention (PCI) with new 
generation DES (n-DES) (n= 4,811), old-generation DES 
(o-DES) (n= 4,271), or bare metal stents (BMS) (n= 
25,065). There was a significantly lower risk of early/late 
stent thrombosis (ST) in patients treated with n-DES 
(hazard ratio -HR: 0.65; p= 0.04) and o-DES (HR: 0.60; 
p= 0.01) compared with the BMS group. The risk of very 
late ST was similar between the n-DES and BMS groups 
(HR: 1.52; p=NS), whereas a higher risk of very late ST 
was observed with o-DES compared with BMS (HR: 2.88; 
p< 0.01). The authors concluded that patients treated with 
n-DES have a lower risk of early/late ST than patients 
treated with BMS. The risk of very late ST is low with n-
DES and BMS up to 3 years, but o-DES are associated with 
an increased risk of very late ST (Sarno G et al, J Am Coll 
Cardiol 2014;64:16–24).  
 
Alcohol Consumption, Even at Moderate Intakes, is a Risk 
Factor for Atrial Fibrillation (AF) 
The association between alcohol consumption and AF 
risk was investigated by following 79,019 men and women 
who, at baseline, were free from AF. At follow-up (1998 
to 2009), 7,245 incident AF cases were identified. The 
association between alcohol consumption and AF did not 
differ by gender. Compared with drinkers of <1 drink/ 
week (12 g alcohol/ drink), the multivariable relative risks 
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(RRs) of AF were 1.01 for 1-6 drinks/week, 1.07 for 7-14 
drinks/week, 1.14 for 15-21 drinks/week, and 1.39 for >21 
drinks/week. Results did not change after excluding binge 
drinkers. In meta-analysis of 7 prospective studies, among 
12,554 AF cases, RRs were 1.08 for 1 drink/day, 1.17 for 
2 drinks/day, 1.26 for 3 drinks/day, 1.36 for 4 drinks/day, 
and 1.47 for 5 drinks/ day, compared with nondrinkers. 
Thus, alcohol, even at moderate intakes, is a risk factor for 
AF (Larsson et al, J Am Coll Cardiol 2014;64:281-289).  
 
TREAT-AF: In Patients With Recently Identified AF, 
Digoxin is Associated With Increased Risk of Death 
According to data of the TREAT-AF study, among 
122,465 male patients (aged 72+10 years) with newly 
diagnosed, nonvalvular atrial fibrillation (AF), 28,679 
(23.4%) received digoxin. Mortality rates were higher for 
those who received digoxin vs those who did not (95 vs 67 
per 1,000 person-years; p< 0.001). Digoxin use was 
independently associated with mortality (hazard ratio -HR: 
1.26, p< 0.001). The risk of death was not modified by age, 
gender, heart failure, kidney function, or concomitant beta-
blocker, amiodarone, or warfarin use. The authors 
concluded that digoxin was associated with increased risk 
of death in patients with newly diagnosed AF, independent 
of drug adherence, kidney function, cardiovascular 
comorbidities, and concomitant therapies. These findings 
challenge current recommendations on use of digoxin in 
AF (Turakhia MP et al, J Am Coll Cardiol 2014;64:660-668).  
 
Blood Transfusions Conferring Higher In-Hospital 
Mortality in Acute Myocardial Infarction (AMI) 
Patients May Merely Reflect a Higher Risk Profile  
Among 34,937 AMI hospitalizations, a total of 1,778 
patients (5.1%) had at least 1 blood transfusion. In 
unadjusted analyses, transfusion conferred higher in-
hospital mortality (odds ratio: 2.05). The majority of 
patients (91.1%) with and without transfusion had non-
overlapping propensity scores, reflecting incomparable 
clinical profiles. After propensity matching those with 
overlapping scores, blood transfusion was associated with 
a reduced risk of in-hospital death (odds ratio: 0.73). The 
authors concluded that the majority of AMI patients 
receiving blood transfusion cannot be matched with non-
transfused patients due to their different clinical profiles. 
Among comparable patients, blood transfusion was 
associated with a lower risk of in-hospital mortality 
(Salisbury AC et al, J Am Coll Cardiol 2014;64:811-819).  
 
European Experience: Percutaneous Transcatheter 
Mitral Valve repair (TMVR) Efficacious in Reducing 
Severity of Primary Mitral Regurgitation (MR) With a 
Relatively Low Complication Rate  
A total of 628 patients (aged 74 ± 10 years, 63% men) 
with mainly (72%) functional mitral regurgitation (FMR) 
(NYHA class >III; logistic EuroScore 20+17) underwent 
TMVR between 1/2011 and 12/2012 in 25 centers in 8 
European countries. Acute success was high (95.4%) with 
one clip implanted in 61.4% of patients. In-hospital 
mortality was low (2.9%). The estimated 1-year mortality 
was 15.3%, which was similar for FMR and degenerative 
MR. The estimated 1-year rate of rehospitalization because 
of heart failure was 22.8%, significantly higher in the FMR 
group (25.8% vs 12.0%, p= 0.009). Paired echocardio-
graphic data (n=368) showed a persistent reduction in the 
degree of MR at 1 year (6% of patients with severe MR). 
The authors concluded that TMVR is associated with high 
immediate success, low complication rates, and sustained 
1-year reduction of the severity of MR and improvement 
of clinical symptoms (Nickenig G et al, J Am Coll Cardiol 
2014;64:875-884).  
 
MADIT-CRT: A Percentage as Low as ≥0.1% of 
Ectopic Beats Leads to <97% Biventricular Paced 
Beats and Higher Risk of Non-Response to CRT 
From the MADIT-CRT, 801 patients with an implanted 
CRT-defibrillator device had data available on 
biventricular pacing percentage and pre-implantation 24-h 
Holter recordings. Ectopic beats accounted for a mean 3.2 
± 5.5% of all beats. The probability of subsequent low 
biventricular pacing percentage (<97%) was increased 3-
fold (odds ratio: 3.37; p < 0.001) in patients with 0.1% - 
1.5% ectopic beats and 13-fold (odds ratio: 13.42; p < 
0.001) in patients with >1.5% ectopic beats compared with 
those with <0.1% ectopic beats. Patients with ≥0.1% 
ectopic beats had significantly less reverse remodeling (p 
< 0.001). The risk of heart failure/death and ventricular 
tachyarrhythmias was increased significantly in those with 
0.1% - 1.5% ectopic beats (hazard ratio: 3.13 and 1.84, 
respectively) and for >1.5% ectopic beats (hazard ratio: 
2.38 and 2.74, respectively). The authors concluded that a 
small percentage of ectopic beats (≥0.1%) dramatically 
increases the probability of low biventricular pacing 
(<97%), with reduced CRT efficacy (Ruwald MH et al, J 
Am Coll Cardiol 2014;64:971-981).  
 
Nadolol Appears to be the Preferred β-Blocker in the 
General Management of Patients With Long QT 
Syndrome (LQTS) 
Among 1,530 LQTS patients receiving β-blockers, 
relative to being off β-blockers, the hazard ratio for first 
cardiac events was 0.71 for atenolol, 0.70 for metoprolol, 
0.65 for propranolol, and 0.51 for nadolol. In LQT1, the 
risk reduction for first cardiac events was similar among 
the 4 β-blockers, but in LQT2, nadolol provided the only 
significant risk reduction (hazard ratio: 0.40). Among 
patients who had a prior cardiac event while taking β-
blockers, efficacy for recurrent events differed by drug (p 
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= 0.004), and propranolol was the least effective. The 
authors concluded that although the 4 β-blockers are 
equally effective in reducing the risk of a first cardiac event 
in LQTS, their efficacy differed by genotype; nadolol was 
the only β-blocker associated with a significant risk 
reduction in patients with LQT2. Patients experiencing 
cardiac events while on β-blocker therapy are at high risk 
for subsequent cardiac events, and propranolol is the least 
effective drug in this high-risk group (Abu-Zeitone A et al, 
J Am Coll Cardiol 2014;64:1352-1358).  
 
ADVANCE III Trial: Programming a Long Detection 
Window Setting in ICDs Leads to a Reduction of 
Electrical Therapies and Shocks Even in the Subgroup 
of Secondary Prevention Patients 
Of the 1902 patients enrolled in the ADVANCE III 
trial, 477 received a defibrillator (ICD) for secondary 
prevention; 248 patients were randomly assigned to a long 
detection setting (30/40 intervals) and 229 to the nominal 
setting (18/24 intervals) for ventricular arrhythmias with 
cycle length ≤320 ms (188 bpm). Over a median period of 
12 months, the long detection period conferred a 25% 
reduction in the number of overall therapies and a 34% 
reduction in the number of ICD shocks. Appropriate 
therapies and appropriate shocks were also reduced. The 
authors concluded that a long detection window setting in 
ICDs leads to a reduction of electrical therapies in both 
primary and secondary prevention populations (Kloppe A 
et al, Circulation 2014;130:308-314).  
 
Bilateral Internal Mammary Artery Grafts Improve 
Long-Term Survival 
 In a meta-analytic approach (9 observational studies, 
15,583 patients), long-term (10-year) survival was 
compared between bilateral (BIMA, n=7313) and single 
internal mammary artery (SIMA, n=8270) grafting. Use of 
BIMA conferred a significant reduction in mortality 
(hazard ratio, 0.79). The authors concluded that BIMA 
grafting appears to have better survival with up to 10 years 
follow-up in comparison with SIMA grafting (Yi G et al, 
Circulation 2014;130:539-545).  
 
Registry Study of 2169 Patients Indicates that Catheter 
Ablation Improves Long-term Outcome in Wolff-
Parkinson-White (WPW) Syndrome 
Among 2169 patients with WPW syndrome, 1168 (206 
asymptomatic) underwent ablation (RFA group) and 1001 
(550 asymptomatic) did not (no-RFA group). Over 8 years, 
in the no-RFA group, VF occurred in 1.5% of patients, 
mostly (13 of 15) in children (median age, 11 years), and 
was associated with a short accessory pathway antegrade 
refractory period (P<0.001) and atrioventricular reentrant 
tachycardia degenerating into atrial fibrillation (P<0.001) 
but not with symptoms. In the RFA group, ablation was 
successful in 98.5%, and after RFA, no patients developed 
malignant arrhythmias or VF. An anterograde effective 
refractory period of the accessory pathway of <240 ms 
predicted VF. The authors concluded that the prognosis of 
the WPW syndrome depends on electrophysiological 
properties of AP rather than on symptoms, and RFA 
improves the long-term outcomes (Pappone C et al, 
Circulation 2014;130:811-819).  
 
Hybrid Coronary Revascularization is Performed in 
1/3 of US Hospitals and May be a Safe Alternative for 
CABG 
 Hybrid (combined surgical and percutaneous) coronary 
revascularization (HCR) represented 0.48% (n=950; 
staged=809, concurrent=141) of the total CABG volume 
(n=198 622) during the period from July 2011 to March 
2013, and was performed in 1/3 of hospitals (n=361) in the 
US. Patients who underwent HCR had higher 
cardiovascular risk profiles. In comparison with CABG, 
median sternotomy direct vision harvesting and 
cardiopulmonary bypass were less frequently used for 
staged and concurrent HCR, whereas robotic assistance 
was more common. No differences were observed for in-
hospital mortality and major morbidity. There was no 
significant association between operative mortality and 
either treatment group. HCR, either as a staged or 
concurrent procedure, is performed in 1/3 of US hospitals, 
and may be an equally safe alternative for CABG 
(Harskamp RE et al, Circulation 2014;130:872-879).  
 
Rate and Predictors if ICD Infection in a Large Cohort 
of Medicare Patients: Avoid Re-Intervention Except 
for Battery Replacement 
Between 2006 and 2009 of 200,909 ICD implants, 3390 
patients (1.7%) developed a device infection. Infection rate 
was 1.4%, 1.5%, and 2.0% for single, dual, and 
biventricular ICDs, respectively (P<0.001). Pulse 
generator replacement had a higher rate compared with 
initial implant (1.9% vs 1.6%, P<0.001). The factors 
associated with infection were adverse re-intervention 
(odds ratio -OR, 2.7), prior valve surgery (OR, 1.5), re-
implantation for device upgrade, malfunction, or 
manufacturer advisory (OR, 1.35), renal failure on dialysis 
(OR, 1.34), chronic lung disease (OR, 1.21), 
cerebrovascular disease (OR, 1.17), and warfarin (OR, 
1.15). The authors concluded that patients who developed 
an ICD infection were more likely to have had peri-ICD 
implant complications requiring early re-intervention, 
previous valve surgery, device replacement for reasons 
other than battery depletion, and increased comorbidity 
burden. Their advice is to avoid reentering the pocket at 
any time other than battery change (Prutkin JM et al, 
Circulation 2014;130:1037-1043).  
 
70 
 
STREAM 1-Year Follow-Up: A Dose-Adjusted 
Pharmaco-invasive Strategy is as Good as Primary PCI 
When Timely Primary PCI is Unattainable in STEMI  
In the STREAM trial, a pharmaco-invasive (PI) 
strategy was compared with primary percutaneous 
coronary intervention (pPCI) in STEMI patients 
presenting within 3 hours after symptom onset but unable 
to undergo pPCI within 1 hour. The PI approach included 
tenecteplase coupled with antiplatelet and anticoagulant 
therapy followed by coronary angiography within 6 - 24 
hours. From 2009 onward the dose of tenecteplase was 
reduced by 50% in patients aged ≥75 years to reduce 
intracranial bleed. For failed thrombolysis, rescue PCI was 
performed. At 30 days, the PI approach was associated 
with nonstatistically lower incidence of the composite 
primary end point of death, shock, congestive heart failure, 
and reinfarction when compared with pPCI. At 1 year, all-
cause mortality (6.7% vs 5.9%) and cardiac mortality rates 
(4.0% vs 4.1%) were similar for PI and pPCI-treated 
patients. Overall, only 34 patients died between day 30 and 
1 year, 20 in the PI arm and 14 in the pPCI arm, of whom 
20 died of noncardiac reasons (13 in the PI and 7 in the 
pPCI arm). The authors concluded that at 1 year, mortality 
rates in the PI and pPCI arms were similar in STEMI 
patients presenting within 3 hours after symptom onset and 
unable to undergo pPCI within 1 hour (Sinnaeve PR et al, 
Circulation 2014;130:1139-1145.)  
 
EFFORTLESS S-ICD Registry: Appropriate 
Performance for the Subcutaneous ICD With Event 
Rates and Inappropriate Shock Rates Comparable 
With Those of Conventional ICDs 
The totally subcutaneous implantable-defibrillator (S-
ICD) is a new alternative to the conventional transvenous 
ICD system to minimize intravascular lead complications. 
The EFFORTLESS S-ICD Registry included 472 patients 
(72% male, aged 49+18 years; mean left ventricular 
ejection fraction 42%). Complication-free rates were 97% 
at 1 month and 94% at 1 year. There were recorded 317 
spontaneous episodes in 85 patients during the 1.5-year 
mean follow-up period; of these, 169 (53%) received 
therapy, 93 being for ventricular tachycardia/fibrillation 
(VT/VF). One patient died of recurrent VF and severe 
bradycardia. First shock conversion efficacy was 88% with 
100% successful clinical conversion after a maximum of 5 
shocks. The 1-year inappropriate shock rate was 7% with 
the majority occurring for oversensing (62/73 episodes), 
primarily (94%) of cardiac signals. The authors concluded 
that the S-ICD has appropriate performance with clinical 
event rates and inappropriate shock rates comparable with 
those reported for conventional ICDs (Lambiase PD et al, 
Eur Heart J 2014; 35:1657–1665).  
 
Dresden NOAC Registry: Peri-Interventional Short-
Term Interruption of Novel Anticoagulants (NOACs) 
is Safe / Bleeding Complications are Related to Major 
Procedures or to Peri-Procedural Heparin Bridging 
 Of 2179 patients receiving NOACs, 595 (27.3%) 
underwent 863 interventional procedures (15.6% minimal, 
74.3% minor, and 10.1% major procedures). Until 1 month 
post-procedure, major cardiovascular events occurred in 
1% and major bleeding complications in 1.2%. 
Cardiovascular (4.6%) and major bleeding complications 
(8%) were highest after major procedures. Heparin 
bridging did not reduce cardiovascular events, but led to 
higher rates of major bleeding (2.7% vs 0.5% with no 
bridging). Diabetes (odds ratio -OR 13.2) and major 
procedures (OR 7.3) were independent risk factors for 
cardiovascular events. Major procedures (OR 16.8) were 
an independent risk factor for major bleeding. The authors 
concluded that continuation or short-term interruption of 
NOAC is safe for most invasive procedures. Patients 
undergoing major procedures may benefit from heparin 
bridging, but at the expense of bleeding risk (Beyer-
Westendorf J et al, Eur Heart J 2014; 35:1888–1896).  
 
CENTURY II Trial: The New Sirolimus-Eluting Co-Cr 
Stent With Bioresorbable Polymer (Ultimaster BP-
SES) is Safe and Effective as Everolimus-Eluting Co-
Cr Stent With Permanent Polymer (Xience PP-EES)  
 The new sirolimus-eluting stent with bioresorbable 
polymer, Ultimaster (BP-SES), was compared with 
everolimus-eluting, permanent polymer, Xience stent (PP-
EES) in 1123 patients undergoing percutaneous coronary 
intervention (PCI). The primary endpoint, freedom from 
target lesion failure (TLF) at 9 months (cardiac death, 
target-vessel-related myocardial infarction and target 
lesion revascularization) was 95.6% with BP-SES and 
95.1% with PP-EES. Composite of cardiac death and MI 
rate was 2.9 and 3.8% (P = NS) and target vessel 
revascularization was 4.5% with BP-SES and 4.2% with 
PP-EES (P = NS). The stent thrombosis rate was 0.9% in 
both arms. The authors concluded that the new 
bioresorbable polymer sirolimus-eluting stent had similar 
safety and efficacy to durable polymer everolimus-eluting 
stent over 9 months (Saiot S et al, Eur Heart J 2014; 
35:2021–2031).  
 
Favorable Long-Term Survival After Alcohol Septal 
Ablation for Hypertrophic Obstructive 
Cardiomyopathy  
 A total of 178 highly symptomatic (87% with dyspnea 
>3 class NYHA) patients with hypertrophic obstructive 
cardiomyopathy (HOCM) (58 ± 12 years, 53% women) 
were treated by alcohol septal ablation (ASA) (1998-
2013). At the most recent examination, 87 patients (49%) 
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had dyspnea NYHA class I and 23 patients (13%) reported 
dyspnea of NYHA class ≥3. The left ventricular outflow 
gradient was significantly reduced (68 ± 42 vs. 20 ± 25 
mmHg; P < 0.01). A total of 19 deaths (11%) occurred 
over 4.8 years (2.1% per year). Survival free of all-cause 
mortality at 1, 5, and 10 years was 97%, 92%, and 82%, 
respectively, which was comparable to the expected 
survival for age- and sex-comparable general population. 
The only independent predictor of all-cause mortality was 
age at ASA (hazard ratio 1.09; P < 0.01). The authors 
concluded that in symptomatic patients with HOCM 
undergoing ASA, long-term survival did not differ from 
that of the general population (Veselka J et al, Eur Heart 
J 2014;35: 2040-2045).  
 
PROFICIO: Large and Rapid Reductions Achievable 
in Apo B and Its Related Lipoproteins, LDL-C, VLDL-
C, and Non-HDL-C With Evolocumab  
A pooled analysis of 1359 patients from 4 phase-2 
studies of evolocumab, a monoclonal antibody to PCSK9, 
showed mean percentage reductions in LDL-C vs placebo 
ranging from 40.2% to 59.3% among the evolocumab 
groups (all P < 0.001). Significant reductions in apo-
lipoprotein B (Apo B), non-high-density lipoprotein 
cholesterol (non-HDL-C), triglycerides and lipoprotein (a) 
- Lp(a), and increases in HDL-C were also observed. 
Adverse events (AEs) and serious AEs with evolocumab 
were reported in 56.8 and 2.0% of patients, compared with 
49.2% and 1.2% with placebo. Cardiac and 
cerebrovascular events were reported in 0.3 and 0% in the 
placebo and 0.9 and 0.3% in the evolocumab arms, 
respectively. The authors concluded that in addition to 
LDL-C reduction, evolocumab, dosed either every 2 weeks 
or every 4 weeks, demonstrated significant and favourable 
changes in other atherogenic and anti-atherogenic 
lipoproteins, and was well tolerated over the 12-week 
treatment period (Stein EA et al, Eur Heart J 2014; 35: 
2249–2259).  
 
REMINDER Study: Compared With Placebo, 
Addition of Eplerenone to Standard Therapy Within 
24 h of Symptom Onset is Safe and Reduces BNP Levels 
of Patients Presenting With STEMI Without Known 
HF or LVEF<40% 
 A total of 1012 patients with STEMI and without a 
history of heart failure (HF) were assigned to receive either 
eplerenone (25–50 mg qd) or placebo in addition to 
standard therapy. The primary endpoint was the composite 
of CV mortality, re-hospitalization, or, extended initial 
hospital stay, due to diagnosis of HF, sustained ventricular 
tachycardia or fibrillation, ejection fraction ≤40%, or 
elevated BNP (>200 pg/mL)/ NT-proBNP (>450 pg/mL, 
age <50; >900 pg/mL, age 50-75; >1800 pg/mL age >75 
years) at 1 month or more after randomization. Over a 
mean of 10.5 months, the primary endpoint occurred in 92 
patients (18.2%) in the eplerenone group and in 149 
patients (29.4%) in the placebo group (hazard ratio - HR, 
0.58; P < 0.0001]. Adverse event rates were similar in both 
groups. Serum potassium levels exceeded 5.5 mmol/L in 
5.6 vs 3.2% (P = 0.09) and were below 3.5 mmol/L in 1.4 
vs 5.6% of patients (P = 0.0002), in the eplerenone and 
placebo groups, respectively. The authors concluded that 
adding eplerenone during the acute phase of STEMI is safe 
and well tolerated. It reduced the primary endpoint over a 
mean 13 months follow-up mostly because of significantly 
lower BNP/NT-proBNP levels (Montalescot G et al, Eur 
Heart J 2014; 35: 2295–2302).  
 
PURE Studies: A Questionable Method of Estimated 
Sodium Excretion (from a Morning Urine Sample), 
Used as a Surrogate for Sodium Intake, Showed a 
Nonlinear Association of Sodium With Blood Pressure, 
Most Pronounced Among Persons Consuming High-
Sodium Diets, Hypertensive and Older Persons / The 
Lowest Risk of Death and Cardiovascular Events was 
Seen at Sodium Excretion of 3-6 g/d. Both Higher and 
Lower Levels of Sodium Excretion Were Associated 
With Increased Risk (a J-Shaped Association Curve)  
A total of 102,216 adults from 18 countries were 
studied. Estimates of 24-hour sodium and potassium 
excretion were made from a single fasting morning urine 
specimen and were used as surrogates for intake. Analysis 
showed increments of 2.11 mm Hg in systolic blood 
pressure and 0.78 mm Hg in diastolic blood pressure for 
each 1-g increment in estimated sodium excretion. The 
slope of this association was steeper with higher sodium 
intake and for hypertensive or older persons. Potassium 
excretion was inversely associated with systolic blood 
pressure. The authors concluded that the association of 
estimated intake of sodium and potassium with blood 
pressure was nonlinear and was most pronounced in 
persons consuming high-sodium diets, and hypertensive 
and older persons (Mente A et al, N Engl J Med 2014; 
371:601-611).  
In the second part of the study, over a mean follow-up 
of 3.7 years, the composite outcome of deaths and major 
cardiovascular events occurred in 3317 participants 
(3.3%). As compared with an estimated sodium excretion 
of 4-6 g/d, a higher estimated sodium excretion (≥7 g/d) 
was associated with an increased risk of the composite 
outcome (odds ratio, 1.15), with strongest association 
among hypertensive participants with an increased risk at 
an estimated sodium excretion of >6 g/d. An estimated 
sodium excretion <3 g/d was also associated with an 
increased risk of the composite outcome (odds ratio, 1.27). 
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Higher potassium excretion was associated with a reduced 
risk of the composite outcome. The authors concluded that 
sodium intake estimated on the basis of measured urinary 
excretion, between 3-6 g/d was associated with a lower risk 
of death and cardiovascular events than was either a higher 
or lower level of intake. Higher potassium excretion was 
associated with a lower risk of death and cardiovascular 
events (O'Donnell M et al, N Engl J Med 2014; 371:612-
623). (The main critique to both these studies relates to the 
estimated sodium intake based on a morning fasting 
midstream urine sample rather than on 24-hour urine 
collection).  
 
NUTRICODE Study: in 2010, a Total of 1.65 Million 
Cardiovascular Deaths Were Attributable to Sodium 
Consumption of >2 g/d (or Salt > 5 g/d)  
Data from surveys on sodium intake, as determined by 
urinary excretion and diet in persons from 66 countries, 
were used to quantify the global consumption of sodium 
according to age, gender, and country. The effects of 
sodium on blood pressure were calculated from data in a 
meta-analysis of 107 randomized interventions, and the 
effects of blood pressure on cardiovascular mortality, 
according to age, were calculated from a meta-analysis of 
cohorts. In 2010, the estimated mean level of global 
sodium consumption was 3.95 g/d. Globally, 1.65 million 
annual deaths from cardiovascular causes were attributed 
to sodium intake above the reference level of >2 g/d (62% 
in men and 38% in women). These deaths accounted for 
nearly 1 of every 10 deaths from cardiovascular causes 
(9.5%). Four of every 5 deaths (84.3%) occurred in low- 
and middle-income countries, and 2 of every 5 deaths 
(40.4%) were premature (< age of 70 years), with highest 
death rate in the country of Georgia and lowest in Kenya. 
The authors concluded that 1.65 million deaths from 
cardiovascular causes that occurred in 2010 were 
attributed to sodium consumption above a reference level 
of 2.0 g/d (> 5 g of salt per day) (Mozaffarian D et al, N 
Engl J Med 2014; 371:624-634).   
 
PARADIGM-HF: Angiotensin Receptor–Neprilysin 
Inhibition With Valsartan/Sucabitril (LCZ696) is 
Superior to ACE Inhibition Alone in Reducing Risks of 
Death and Hospitalization for Heart Failure / Strong 
Evidence that Combined Inhibition of the Angiotensin 
Receptor and Neprilysin is Superior to Inhibition of the 
Renin–Angiotensin System Alone in Patients With 
Chronic Heart Failure  
A total of 8442 patients with class II-IV heart failure 
and an ejection fraction of <40% were randomly assigned 
to receive either valsartan/sucabitril (LCZ696) (200 mg 
bid) or enalapril (10 mg bid), in addition to recommended 
therapy. The trial was stopped early at a median follow-up 
of 27 months. The primary outcome (composite of death 
from cardiovascular causes or hospitalization for heart 
failure) had occurred in 914 patients (21.8%) in the 
LCZ696 group and 1117 patients (26.5%) in the enalapril 
group (hazard ratio-HR 0.80; P<0.001); mortality was 17% 
vs 19.8% (HR, 0.84; P<0.001), and cardiovascular 
mortality 13.3% vs 16.5% (HR, 0.80; P<0.001), 
respectively. The new drug decreased the risk of 
hospitalization for heart failure by 21% (P<0.001). The 
new drug caused higher rates of hypotension and 
nonserious angioedema but lower rates of renal 
impairment, hyperkalemia, and cough than enalapril. The 
authors concluded that LCZ696 was superior to enalapril 
in reducing the risks of death and of hospitalization for 
heart failure (McMurray JJV et al, N Engl J Med 2014; 
371:993-1004).  
 
ATLANTIC study: Prehospital Ticagrelor in STEMI is 
not Necessary  
A total of 1862 patients with STEMI of <6 hours' 
duration received ticagrelor as prehospital (in the 
ambulance) or in-hospital (in the catheterization 
laboratory) treatment (median time from randomization to 
angiography: 48 min; median time difference between the 
two treatment strategies: 31 min). The two coprimary end 
points (proportion of patients who did not have a >70% 
resolution of ST elevation before PCI and those who did 
not have TIMI flow grade 3 in the infarct-related artery at 
initial angiography) did not differ between the 2 groups. 
The absence of ST-elevation resolution of >70% after PCI 
(secondary end point) was reported for 42.5% and 47.5% 
of patients, respectively. Rates of major adverse 
cardiovascular events did not differ between the 2 groups. 
Rates of definite stent thrombosis were lower in the 
prehospital group (0% vs 0.8% in the first 24 hours; 0.2% 
vs 1.2% at 30 days). Rates of major bleeding were low and 
similar in the 2 groups. The authors concluded that 
prehospital administration of ticagrelor in patients with 
STEMI was safe but did not improve pre-PCI coronary 
reperfusion (Montalescot G et al, N Engl J Med 2014; 
371:1016-1027).  
 
SIGNIFY: No Benefit of Ivabradine in Patients With 
Stable Coronary Artery Disease Without Clinical 
Heart Failure 
A total of 19,102 patients with stable coronary artery 
disease (CAD) and heart rate >70 bpm without heart 
failure were randomized to ivabradine (10 mg bid) to 
achieve a heart rate of 55 - 60 bpm. At 3 months, heart rate 
was 60.7±9 bpm in the ivabradine group vs 70.6±10.1 bpm 
in the placebo group. After a median follow-up of 27.8 
months, there was no significant difference between the 2 
groups in the primary end point (composite of death from 
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cardiovascular causes or nonfatal myocardial infarction) 
(6.8% and 6.4%, respectively; hazard ratio, 1.08; P=NS). 
The incidence of bradycardia was higher with ivabradine 
(18% vs 2.3%, P<0.001). The authors concluded that in 
patients with stable CAD without clinical heart failure, the 
addition of ivabradine to standard therapy to reduce the 
heart rate did not improve outcomes (Fox K et al, N Engl 
J Med 2014; 371:1091-1099).  
 
TASTE at 1 Year: No Benefit of Thrombus Aspiration 
for Myocardial Infarction (MI) 
A total of 7244 patients with STEMI were randomly 
assigned to undergo manual thrombus aspiration followed 
by PCI or PCI alone, in a registry-based, randomized 
clinical trial. Mortality at 1 year was 5.3% in the thrombus-
aspiration group vs 5.6% in the PCI-only group (hazard 
ratio-HR, 0.94; P=NS). Re-hospitalization for MI at 1 year 
occurred in 2.7% and 2.7% of the patients (HR, 0.97; 
P=NS), and stent thrombosis in 0.7% and 0.9%, 
respectively (HR, 0.84; P=NS). The composite of death 
from any cause, rehospitalization for MI, or stent 
thrombosis occurred in 8.0% and 8.5% of patients, 
respectively (HR, 0.94; P=NS). The authors concluded that 
routine thrombus aspiration before PCI in patients with 
STEMI did not reduce the rate of death from any cause or 
the composite of death from any cause, rehospitalization 
for myocardial infarction, or stent thrombosis at 1 year 
(Lagerqvist B et al, N Engl J Med 2014; 371:1111-1120).  
 
FAME 2: Favorable Results From Fractional Flow 
Reserve–Guided PCI in Stable Coronary Disease 
In 1220 patients with stable coronary artery disease, 
fractional flow reserve (FFR) was assessed in all coronary 
stenoses. Patients with >1 stenosis with an FFR of <0.80 
were randomly assigned to undergo FFR-guided PCI plus 
medical therapy or to receive medical therapy alone. 
Patient with all stenoses having FFR >0.80 received 
medical therapy alone (included in a registry). The primary 
end point (composite of death from any cause, nonfatal MI, 
or urgent revascularization within 2 years) was 
significantly lower in the PCI group (8.1% vs 19.5%; 
hazard ratio-HR, 0.39; P<0.001), driven by a lower rate of 
urgent revascularization (4.0% vs 16.3%; HR, 0.23; 
P<0.001); there were no between-group differences in 
rates of death and MI. Urgent revascularizations were less 
frequent in the PCI group (3.4% vs 7.0%, P=0.01). Rate of 
death or MI from 8 days to 2 years was lower in the PCI 
group (4.6% vs 8.0%, P=0.04). In the registry patients, the 
rate of the primary end point was 9.0% at 2 years. The 
authors concluded that in patients with stable coronary 
artery disease, FFR-guided PCI improved the outcome. 
Patients without ischemia (normal FFR) had a favorable 
outcome with medical therapy alone (De Bruyne B et al, N 
Engl J Med 2014; 371:1208-1217).  
 
ARIC: an Elevated (≥140 mmHg) Systolic BP Carries 
the Highest Risk for Cardiovascular Events / BP <120 
Confers no Additional Benefit Compared With BP<140 
Among 4480 individuals with hypertension (HTN) but 
without prevalent cardiovascular (CV) disease at baseline, 
a total of 1622 incident CV events (heart failure, ischemic 
stroke, myocardial infarction, or death related to coronary 
heart disease) occurred over a median follow-up of ~22 
years. Elevated (>140 mmHg) systolic blood pressure 
(SBP) conferred significantly more CV events than low BP 
(<120 mmHg) (hazard ratio -HR, 1.46), with no difference 
noted in the standard (120-140 mmHg) vs low SBP group 
(HR, 1.00). No effect related to BP medication use or 
diastolic BP was observed. The authors concluded that 
among patients with HTN, an elevated SBP carries the 
highest risk for CV events, but once SBP was <140 mmHg, 
an SBP <120 mmHg did not appear to lessen the risk 
(Rodriguez CJ, JAMA Intern Med 2014;174:1252-1261).  
 
83% 1-Year Survival after Transcatheter Valve-in-
Valve Implantation  
A multinational registry included 459 patients with 
degenerated bioprosthetic valves undergoing valve-in-
valve implantation (2007 – 2013) with both balloon- and 
self-expandable valves. Within 1 month, 35 (7.6%) 
patients died, 8 (1.7%) had major stroke, and 313 (92.6%) 
of surviving patients had good functional status (New York 
Heart Association class I/II). Overall 1-year survival rate 
was 83.2% (62 death events; 228 survivors). Patients in the 
stenosis group had worse survival (76.6%) in comparison 
with the regurgitation (91.2%) and the combined group 
(83.9%) (P = 0.01). Patients with small valves had worse 
1-year survival (74.8%) vs with intermediate-sized valves 
(81.8%) and with large valves (93.3%) (P = .001). Factors 
associated with 1-year mortality included small surgical 
bioprosthesis (≤21 mm; hazard ratio, 2.04; P = .02) and 
baseline stenosis (vs regurgitation; hazard ratio, 3.07; 
P = .008). The authors concluded that in this registry of 
patients who underwent transcatheter valve-in-valve 
implantation for degenerated bioprosthetic aortic valves, 
overall 1-year survival was 83%. Survival was lower 
among patients with small bioprostheses and those with 
predominant surgical valve stenosis (Dvir D et al, JAMA 
2014;312:162-170).  
 
Perioperative Atrial Fibrillation (AF) Confers High 
Long-term Risk of Ischemic Stroke  
In a retrospective study (2007-2011) of 1,729,360 
patients hospitalized for surgery, 24,711 (1.43%) had new-
onset perioperative AF and 13,952 (0.81%) had a stroke 
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after discharge. At 1 year after cardiac surgery, stroke rate 
was 0.99% in those with perioperative AF and 0.83% in 
those without AF. At 1 year after noncardiac surgery, 
stroke rate was 1.47% in those with perioperative AF and 
0.36% in those without AF. Perioperative AF was 
associated with subsequent stroke both after cardiac 
(hazard ratio-HR, 1.3) and noncardiac surgery (HR, 2.0). 
The authors concluded that among patients having surgery, 
perioperative AF conferred an increased long-term risk of 
ischemic stroke, especially after noncardiac surgery 
(Gialdini G et al, JAMA 2014;312:616-622).  
 
SOLID-TIMI 52: No Benefit of Darapladib on Major 
Coronary Events After an Acute Coronary Syndrome  
A total of 13 026 patients were randomized (2009-
2013) within 30 days of an acute coronary syndrome 
(ACS) to either once-daily darapladib (160 mg) (an oral, 
selective inhibitor of lipoprotein-associated phospholipase 
A2 - Lp-PLA2) or placebo. During a median of 2.5 years, 
major coronary events occurred in 903 patients in the 
darapladib group and 910 in the placebo group (16.3% vs 
15.6% at 3 years; hazard ratio - HR, 1.00; P = NS). There 
was no difference between the treatment groups in all-
cause mortality (7.3% vs 7.1% at 3 years; HR, 0.94; 
P = NS). Darapladib caused more diarrhea and an odor-
related concern. The authors concluded that in patients 
with ACS, direct inhibition of Lp-PLA2 with darapladib 
added to optimal medical therapy and initiated within 30 
days of hospitalization did not reduce the risk of major 
coronary events (O’Donoghue ML et al, JAMA 
2014;312:1006-1015).  
 
Meta-Analysis: Bivalirudin Increases MACE 
Compared With Heparin in Patients Planned for 
Percutaneous Coronary Intervention (PCI) 
Data from 16 trials involving 33,958 patients indicated 
an increase in the risk of major adverse cardiac events 
(MACE) with bivalirudin-based regimens compared with 
heparin-based regimens (risk ratio-RR 1.09; p=0·0204), 
largely driven by increases in myocardial infarction (MI) 
(RR 1.12) and ischemia-driven revascularisation (RR 
1.16), with no effect on mortality (RR 0.99). Bivalirudin 
increased the risk of stent thrombosis (RR 1.38; p=0.0074), 
primarily due to an increase in acute cases of MI (RR 4.27; 
p<0·0001). Overall, bivalirudin-based regimens lowered 
the risk of major bleeding (RR 0.62; p<0·0001), but the 
magnitude of this effect varied (p<0·0001) depending on 
whether glycoprotein IIb/IIIa inhibitors were used. The 
authors concluded that compared with a heparin-based 
regimen, a bivalirudin-based regimen increases the risk of 
MI and stent thrombosis, but decreases the risk of bleeding 
(Cavender MA & Sabatine MS, Lancet 2014; 384 (9943): 
599 – 606).  
Important Review and Other Articles  
 
Renal denervation for treatment of cardiac arrhythmias 
(Kosiuk J et al, J Cardiovasc Electrophysiol 2014 Sep 18. 
doi: 10.1111/jce.12553. [Epub ahead of print], 2014 AHA/ 
ACC Guideline for the management of patients with NSTE 
ACS (Amsterdam EA et al, J Am Coll Cardiol 2014; doi: 
10.1016/j.jacc.2014.09.017), The MOGE(S) classification 
of cardiomyopathy (J Am Coll Cardiol 2014;64:304-318), 
Hypertrophic cardiomyopathy (Baron et al, J Am Coll 
Cardiol 2014;64:83-99), Aspirin in primary 
cardiovascular disease prevention (Halvorsen S et al, J Am 
Coll Cardiol 2014;64:319-327), Rhythm control in heart 
failure patients with AF (Trulock KM et al, J Am Coll 
Cardiol 2014;64:710-721), Carotid artery stenting (White 
CJ, J Am Coll Cardiol 2014;64:722-731), AF ablation 
(Nishida K et al, J Am Coll Cardiol 2014;64:823-831), 
Fibromuscular dysplasia involving coronary arteries 
(Michelis KC et al, J Am Coll Cardiol 2014;64:1033-
1046), CRT (Leyva F et al, J Am Coll Cardiol 
2014;64:1047-1058), ICDs in patients not included or not 
well represented in clinical trials (Kusumoto FM et al, J 
Am Coll Cardiol. 2014;64(11):1143-1177), Triple therapy 
for AF and PCI (Dewilde W et al, J Am Coll Cardiol 
2014;64:1270-1280), Chronic total occlusions (Strauss BH 
et al, J Am Coll Cardiol 2014;64:1281-1289), 
Superresponse to CRT (Steffel J & Ruschitzka F, 
Circulation 2014;130:87-90), Left atrial appendage 
closure in patients with AF (Price MJ & Valderrabano M, 
Circulation 2014;130:202-212), Cardiovascular 
management in pregnancy (Brickner ME, Circulation 
2014;130:273-282), Chronic venous insufficiency 
(Eberhardt RT & Raffetto JD, Circulation 2014;130:333-
346), Chronic thromboembolic pulmonary hypertension 
(Lang IM & Madani M, Circulation 2014;130:508-518), 
Anderson-Fabry disease (Nagueh SF, Circulation 
2014;130:1081-1090), Risk stratification for sudden 
cardiac death (Wellens HJJ et al, Eur Heart J 2014;35: 
1642-1651), Edoxaban (Lip G & Agnelli G, Eur Heart J 
2014;35: 1844-1855), Post-infarct ventricular septal 
rupture (Jones BM et al, Eur Heart J 2014;35: 2060-2068), 
Aortic stenosis and coronary artery disease (Paradis J et al, 
Eur Heart J 2014;35: 2069-2082), Cardiac tamponade 
(Ristic AD et al, Eur Heart J 2014;35: 2279-2284), 
Catheter ablation of AF (Haegeli LM & Calkins H, Eur 
Heart J 2014;35: 2454-2459), Aortic stenosis (Otto CM & 
Prendergast B, N Engl J Med 2014; 371:744-756), 
Screening for abdominal aortic aneurysm (LeFevre ML et 
al, Ann Intern Med 2014; 161: 281-290), Screening for 
asymptomatic carotid artery stenosis (Jonas DE et al, Ann 
Intern Med 2014;161:336-346; LeFevre ML et al, Ann 
Intern Med 2014;161:356-362).  
